CD14+CD16++ monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy

J Neuroimmunol. 2016 Nov 15:300:1-8. doi: 10.1016/j.jneuroim.2016.09.011. Epub 2016 Sep 30.

Abstract

The pathophysiologic significance of the CD16+ monocyte subset has been demonstrated by its expansion in various autoimmune disorders. To date, the characteristics and roles of monocyte subpopulations in patients with neuromyelitis optica (NMO) have been poorly defined. We measured the percentages of the monocyte subsets in the peripheral blood, the levels of IL-1β and TNF-α mRNA in monocyte subsets and the concentrations of IL-1β and TNF-α in plasma and CSF from NMO patients. Our results showed that nonclassical monocytes were up-regulated in NMO patients and significantly elevated IL-1β and TNF-α expression was detected in it. In addition the increased nonclassical monocytes could be selectively suppressed by GC in patients with NMO.

Keywords: Flow cytometry; Glucocorticoids; Interleukin-1beta; Monocyte subsets; Neuromyelitis optica; Tumor necrosis factor-alpha.

MeSH terms

  • Adult
  • Female
  • Flow Cytometry / methods
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use*
  • Humans
  • Lipopolysaccharide Receptors / blood*
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / metabolism*
  • Neuromyelitis Optica / blood*
  • Neuromyelitis Optica / drug therapy*
  • Receptors, IgG / blood*

Substances

  • Glucocorticoids
  • Lipopolysaccharide Receptors
  • Receptors, IgG